Tango Therapeutics Inc
$ 21.50
-6.93%
02 Jun - close price
- Market Cap 3,203,953,000 USD
- Current Price $ 21.50
- High / Low $ 23.05 / 21.36
- Stock P/E N/A
- Book Value 2.55
- EPS -0.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.38 %
- 52 Week High 28.41
- 52 Week Low 2.96
About
Tango Therapeutics Inc. is a pioneering clinical-stage biotechnology company dedicated to transforming cancer treatment with its innovative focus on synthetic lethality and targeted therapies. The company's extensive pipeline features a range of promising drug candidates aimed at precision oncology, positioning it as a key player in the field. By forging strategic collaborations with leading academic institutions, Tango enhances its research capabilities and strengthens its commitment to addressing significant unmet needs in cancer care. Through its forward-thinking approach, Tango Therapeutics seeks to significantly improve patient outcomes and reshape treatment standards in oncology.
Analyst Target Price
$31.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-05 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-02-27 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 |
| Reported EPS | -0.32 | -0.29 | -0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Estimated EPS | -0.2967 | -0.319 | -0.07 | -0.35 | -0.3459 | -0.3428 | -0.37 | -0.34 | -0.31 | -0.28 | -0.34 | -0.34 |
| Surprise | -0.0233 | 0.029 | -0.07 | 0 | -0.0141 | 0.0028 | 0.1 | 0.1 | -0.04 | -0.04 | 0.11 | 0.11 |
| Surprise Percentage | -7.8531% | 9.0909% | -100% | 0% | -4.0763% | 0.8168% | 27.027% | 29.4118% | -12.9032% | -14.2857% | 32.3529% | 32.3529% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-05-28 16:40:18
Tango Therapeutics reported wider net losses in Q1 2026, reaching US$45.51 million, alongside significant board changes including two resignations and Sung Lee's elevation to Lead Independent Director. The company remains an oncology platform with high investment risk tied to clinical execution rather than current profits, with future dilution and cash burn being significant concerns for investors. Analysts view the company's fair value estimations widely, ranging from US$10 to US$31.90.
2026-05-27 19:40:23
Tango Therapeutics reported wider net losses in Q1 2026, reaching US$45.51 million, though basic loss per share narrowed. The company also underwent significant board changes, with two directors resigning and Sung Lee becoming Lead Independent Director. These developments suggest an evolving investment narrative focused on clinical execution and governance, with investors needing to consider ongoing cash burn and dilution risks.
2026-05-26 13:10:16
TNGX stock dropped 20% after the company reported zero revenue in its first-quarter earnings, despite having 15 active clinical trials. Analysts, however, maintain "Strong Buy" ratings and significant price targets, indicating potential for future growth based on its drug pipeline. The stock has experienced high volatility, with a substantial year-to-date decline but also significant surges since its IPO.
2026-05-22 15:09:36
CCORF has reaffirmed its 'Buy' rating for Tango Therapeutics (TNGX.US) and maintained its price target of $30. This indicates a continued positive outlook on the company's stock performance.
2026-05-20 01:39:48
Tango Therapeutics (TNGX) saw its stock drop by 12.4% following its first-quarter 2026 results, which reported a net loss of US$45.51 million and no collaboration revenue due to the end of its partnership with Gilead. Additionally, board members Alexis Borisy and Kanishka Pothula resigned. Despite these setbacks, the company highlighted having US$379.80 million in cash, expected to fund operations into 2028, and continues to progress its precision oncology pipeline.
2026-05-18 08:41:38
Tango Therapeutics (TNGX) saw its stock drop 12.4% after reporting a wider Q1 2026 net loss of US$45.51 million and the end of its collaboration revenue with Gilead. The company also announced board resignations but highlighted US$379.80 million in cash, expected to fund operations into 2028, and ongoing progress in its precision oncology pipeline. The investment narrative focuses on the reliance on unproven trials to justify spending without near-term profitability, especially following the loss of the Gilead partnership.
